Evaluating Metrics of Circulating Tumor DNA Response and Progression Using a High Sensitivity Tumor-Agnostic Assay in Metastatic HR+/HER2- Breast Cancer Receiving Endocrine Therapy and a CDK4/6-inhibitor.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined